Data analyzed from the phase 2 CENTAUR trial showed a significant reduction in YKL-40 and C-reactive protein, but not chitinase 1, over 24 weeks, with reductions observed as early as week 12. These biomarkers have been previously shown to correlate with ALS disease progression.

An analysis of top-line data from the 6-month double-blind segment of the PARADIGM trial showed significant slowing of disease progression with a 37.4% difference in ALSFRS-R and a 17.2% difference in slow vital capacity in participants taking PrimeC versus placebo.

The Symposium, held December 6-8 in Basel, Switzerland, is the largest medical and scientific conference focused on ALS.

More News:

Health Canada Authorizes First Study of Prosetin in People Living with ALS

BrainStorm, FDA Agree on Next Steps for Phase 3b Testing of NurOwn

Unusual RNA Structures Could be Targets for New ALS Treatments

Study Explores Link Between Traumatic Brain Injury and Onset of ALS/FTD

Mutations in SPTLC2 Gene Linked to Juvenile-Onset ALS

Specialized Motor Neuron Region Affected in ALS, New Study Finds

ALS Focus is a survey program developed by and for people living with ALS and their caregivers. Through ALS Focus research, the ALS Association scientifically measures the preferences, needs and experiences of people living with ALS and ALS caregivers to promote change in ALS research, policy, and care. All participants must be at least 18 years old, live in the United States and be able to read and understand English.

By sharing their lived experiences, ALS Focus participants can make a real difference for the ALS community. More information about ALS Focus and instructions for signing up can be found at ALSFocus.org.

Breaking Down Barriers: Trial Capacity Awardees Work to Improve Access to ALS Clinical Trials

Subscribe today to follow our weekly blog and stay up to date with what’s happening in the ALS community. Visit our website HERE.

Clinical research is the only way that promising laboratory science can be translated into treatments and cures for ALS and other neurological diseases. People with ALS, along with family members and caregivers, are essential partners in this research. For the most accurate and up-to-date information on both federally and privately funded clinical studies focusing on ALS and other similar motor neuron diseases, visit our website.

The National ALS Registry may be the single largest ALS research project ever created and is designed to identify ALS cases from throughout the entire United States. Every person living with ALS in the U.S. can take part, and there is no fee to participate. 

The ALS Association partners with the Northeast ALS Consortium (NEALS) to provide educational webinars for people with ALS, caregivers, and the broader ALS community. Topics include updates on clinical trials, best practices for clinical care, and current research efforts in ALS causes and treatments. 

For more details about current ALS research, our programs and awards, and the projects we fund, visit als.org/research.

Stay up to date with the latest news in ALS care by signing up for our quarterly e-newsletter, Care Matters.

We welcome all feedback, comments and questions you may have on anything about the information provided, suggestions of topics you would like to see in future newsletters or thoughts to help us improve. Please email us at communications@als.org.

Research Matters will arrive in your inbox on the last Thursday of each month. To unsubscribe from future issues, please update your email preferences.

Data analyzed from the phase 2 CENTAUR trial showed a significant reduction in YKL-40 and C-reactive protein, but not chitinase 1, over 24 weeks, with reductions observed as early as week 12. These biomarkers have been previously shown to correlate with ALS disease progression.

An analysis of top-line data from the 6-month double-blind segment of the PARADIGM trial showed significant slowing of disease progression with a 37.4% difference in ALSFRS-R and a 17.2% difference in slow vital capacity in participants taking PrimeC versus placebo.

The Symposium, held December 6-8 in Basel, Switzerland, is the largest medical and scientific conference focused on ALS.

More News:

Health Canada Authorizes First Study of Prosetin in People Living with ALS

BrainStorm, FDA Agree on Next Steps for Phase 3b Testing of NurOwn

Unusual RNA Structures Could be Targets for New ALS Treatments

Study Explores Link Between Traumatic Brain Injury and Onset of ALS/FTD

Mutations in SPTLC2 Gene Linked to Juvenile-Onset ALS

Specialized Motor Neuron Region Affected in ALS, New Study Finds

ALS Focus is a survey program developed by and for people living with ALS and their caregivers. Through ALS Focus research, the ALS Association scientifically measures the preferences, needs and experiences of people living with ALS and ALS caregivers to promote change in ALS research, policy, and care. All participants must be at least 18 years old, live in the United States and be able to read and understand English.

By sharing their lived experiences, ALS Focus participants can make a real difference for the ALS community. More information about ALS Focus and instructions for signing up can be found at ALSFocus.org.

Breaking Down Barriers: Trial Capacity Awardees Work to Improve Access to ALS Clinical Trials

Subscribe today to follow our weekly blog and stay up to date with what’s happening in the ALS community. Visit our website HERE.

Clinical research is the only way that promising laboratory science can be translated into treatments and cures for ALS and other neurological diseases. People with ALS, along with family members and caregivers, are essential partners in this research. For the most accurate and up-to-date information on both federally and privately funded clinical studies focusing on ALS and other similar motor neuron diseases, visit our website.

The National ALS Registry may be the single largest ALS research project ever created and is designed to identify ALS cases from throughout the entire United States. Every person living with ALS in the U.S. can take part, and there is no fee to participate. 

The ALS Association partners with the Northeast ALS Consortium (NEALS) to provide educational webinars for people with ALS, caregivers, and the broader ALS community. Topics include updates on clinical trials, best practices for clinical care, and current research efforts in ALS causes and treatments. 

For more details about current ALS research, our programs and awards, and the projects we fund, visit als.org/research.

Stay up to date with the latest news in ALS care by signing up for our quarterly e-newsletter, Care Matters.

We welcome all feedback, comments and questions you may have on anything about the information provided, suggestions of topics you would like to see in future newsletters or thoughts to help us improve. Please email us at communications@als.org.